West Pharmaceutical Services (NYSE:WST - Get Free Report) issued an update on its FY24 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of $6.55 to $6.75 for the period, compared to the consensus estimate of $6.42. The company issued revenue guidance of $2.875 billion to $2.905 billion from $2.870 billion to $2.900, compared to the consensus revenue estimate of $2.87 billion. West Pharmaceutical Services also updated its FY 2024 guidance to 6.550-6.750 EPS.
West Pharmaceutical Services Trading Up 15.4 %
NYSE:WST traded up $44.21 during trading hours on Thursday, hitting $330.65. 1,983,070 shares of the company were exchanged, compared to its average volume of 558,379. The stock has a market capitalization of $23.99 billion, a price-to-earnings ratio of 47.03, a price-to-earnings-growth ratio of 10.21 and a beta of 1.01. West Pharmaceutical Services has a one year low of $265.00 and a one year high of $413.70. The company has a fifty day simple moving average of $299.60 and a 200 day simple moving average of $322.81. The company has a current ratio of 2.34, a quick ratio of 1.68 and a debt-to-equity ratio of 0.03.
West Pharmaceutical Services (NYSE:WST - Get Free Report) last issued its quarterly earnings data on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.74 by ($0.22). The company had revenue of $702.10 million for the quarter, compared to the consensus estimate of $729.36 million. West Pharmaceutical Services had a return on equity of 19.17% and a net margin of 18.25%. West Pharmaceutical Services's revenue was down 6.9% compared to the same quarter last year. During the same quarter last year, the business earned $2.11 earnings per share. Sell-side analysts expect that West Pharmaceutical Services will post 6.42 EPS for the current fiscal year.
Insider Transactions at West Pharmaceutical Services
In other news, VP Charles Witherspoon sold 1,029 shares of the business's stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $300.00, for a total value of $308,700.00. Following the transaction, the vice president now directly owns 1,478 shares of the company's stock, valued at $443,400. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.53% of the company's stock.
West Pharmaceutical Services Company Profile
(
Get Free Report)
West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
See Also
Before you consider West Pharmaceutical Services, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.
While West Pharmaceutical Services currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for November 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
